Top-News

Epizyme News

Aktie
WKN:  A1T9L2 ISIN:  US29428V1044 US-Symbol:  EPZM
Keine aktuellen Kursdaten verfügbar
Handeln Depot/Watchlist
Dieses Wertpapier ist nicht mehr handelbar.
Aktienanzahl *
168,33 Mio.
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 12.08.2022

Epizyme News

25.07.22 - PR Newswire
SHAREHOLDER ALERT: Weiss Law Reminds WWE, DRE, MN, and EPZM Shareholders About Its Ongoing Investigations
SHAREHOLDER ALERT: Weiss Law Reminds WWE, DRE, MN, and EPZM Shareholders About Its Ongoing Investigations PR Newswire
14.07.22 - PR Newswire
SHAREHOLDER ALERT: Weiss Law Reminds RFP, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations
SHAREHOLDER ALERT: Weiss Law Reminds RFP, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations PR Newswire
06.07.22 - PR Newswire
SHAREHOLDER ALERT: Weiss Law Reminds FSTX, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations
SHAREHOLDER ALERT: Weiss Law Reminds FSTX, ZEN, RDUS, and EPZM Shareholders About Its Ongoing Investigations PR Newswire
06.07.22 - PR Newswire
Moore Kuehn Encourages EPZM, RDUS, OBCI, and CNVY Investors to Contact Law Firm
Moore Kuehn Encourages EPZM, RDUS, OBCI, and CNVY Investors to Contact Law Firm PR Newswire
05.07.22 - PR Newswire
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates ZEN, USAK, EPZM
INVESTIGATION NOTICE: Halper Sadeh LLP Investigates ZEN, USAK, EPZM PR Newswire
27.06.22 - PR Newswire
Shareholder Alert - The M&A Class Action Firm Announces an Investigation of Epizyme, Inc. - EPZM
Shareholder Alert - The M&A Class Action Firm Announces an Investigation of Epizyme, Inc. - EPZM PR Newswire
27.06.22 - PR Newswire
SHAREHOLDER ALERT: Weiss Law Investigates Epizyme, Inc.
SHAREHOLDER ALERT: Weiss Law Investigates Epizyme, Inc. PR Newswire
27.06.22 - PR Newswire
Shareholder Alert: Ademi LLP investigates whether Epizyme, Inc. has obtained a Fair Price in its transaction with Ipsen
Shareholder Alert: Ademi LLP investigates whether Epizyme, Inc. has obtained a Fair Price in its transaction with Ipsen PR Newswire
27.06.22 - PR Newswire
Thinking about buying stock in Epizyme, Acutus Medical, Agile Therapeutics, Axsome Therapeutics, or Evofem Biosciences?
Thinking about buying stock in Epizyme, Acutus Medical, Agile Therapeutics, Axsome Therapeutics, or Evofem Biosciences? PR Newswire
27.06.22 - Der Aktionär
144 Prozent Aufschlag! Nächste Übernahme im Biotech‑Sektor
07.05.21 - PR Newswire
Thinking about buying stock in Epizyme, AMC Entertainment, Evofem Biosciences, Nokia, or Arcutis Biotherapeutics?
Thinking about buying stock in Epizyme, AMC Entertainment, Evofem Biosciences, Nokia, or Arcutis Biotherapeutics? PR Newswire
05.11.19 - PR Newswire
Royalty Pharma Announces Agreement to Purchase Future Royalties on Tazemetostat from Eisai for $330 Million and a $100 Million Initial Investment in Epizyme
Royalty Pharma Announces Agreement to Purchase Future Royalties on Tazemetostat from Eisai for $330 Million and a $100 Million Initial Investment in Epizyme Pharmakon Funds ...
10.06.14 - PR Newswire
Epizyme to Give Oral Presentation on Pre-Clinical Models and Early Clinical Observations of EZH2 Inhibitor EPZ-6438 at ASH Meeting on Lymphoma Biology August 10-13, 2014
Epizyme to Give Oral Presentation on Pre-​Clinical Models and Early Clinical Observations of EZH2 Inhibitor EPZ-6438 at ASH Meeting on Lymphoma Biology August 10-13, 2014 PR ...
28.05.14 - PR Newswire
Epizyme, Inc. to Present at Upcoming Conferences in June
Epizyme, Inc. to Present at Upcoming Conferences in June PR Newswire
13.05.14 - PR Newswire
Epizyme Announces First Quarter 2014 Financial Results and Provides Corporate Update
Epizyme Announces First Quarter 2014 Financial Results and Provides Corporate Update -- Initiated pediatric MLL-r Phase 1b dose escalation study of DOT1L inhibitor EPZ-5676 in ...
07.05.14 - PR Newswire
Epizyme, Inc. to Report First Quarter Financial Results and Provide Corporate Update on May 13, 2014
Epizyme, Inc. to Report First Quarter Financial Results and Provide Corporate Update on May 13, 2014 PR Newswire
02.05.14 - PR Newswire
Epizyme, Inc. to Present at Upcoming Conferences in May
Epizyme, Inc. to Present at Upcoming Conferences in May PR Newswire
02.05.14 - PR Newswire
Epizyme Nominates Dr. Andrew R. Allen For Election to Board of Directors
Epizyme Nominates Dr. Andrew R. Allen For Election to Board of Directors PR Newswire
30.04.14 - PR Newswire
Epizyme Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treatment for Cancers with EZH2 Inhibitors
Epizyme Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treatment for Cancers with EZH2 Inhibitors Patent covers methods of use for small ...
25.04.14 - PR Newswire
Epizyme Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treatment for Cancers with EZH2 Inhibitors
Epizyme Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treatment for Cancers with EZH2 Inhibitors Patent covers methods of use for small ...

Newssuche

Videos

13.06.24 0,00%
Technical Trading: Zukauf-​Chance bei Top-Trade, wenn
Sugar No.11 Long Typ: Turbo Open End WKN: VV50DP Hebel: 5 Laufzeit: OpenEnd Einstieg: prozyklisch ... Mehr »